Novalis LifeSciences
Novalis Lifesciences is a globally acting venture capital firm focused on breakthrough technologies in Life Science.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Novalis LifeSciences Information
Geographic Data
Address: 1 Liberty Lane E
City: Hampton
State: NH
Zip: 03842
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$385M
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Novalis Lifesciences LLC, is a globally acting venture capital firm focused on breakthrough technologies in Life Science. Founded and managed by Dr. Marijn E. Dekkers, current chairman of Unilever and former chief executive officer of Bayer AG and Thermo Fisher Scientific Inc., Novalis works with a diversified group of project-based specialists leading in their respective life science fields
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2020 | Allurion Technologies | Debt | 34M |
| 6/2020 | eTheRNA immunotherapies | Series B | 0 |
| 12/2021 | SkylineDx | Venture Round | - |
| 1/2022 | Ori Biotech | Series B | 0 |
| 6/2020 | Enko Chem | Series B | 0 |
| 7/2021 | Allurion Technologies | Series D | 34M |
| 6/2022 | Vizgen | Series C | 0 |
| 4/2021 | Vizgen | Series B | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | Sherlock Biosciences | Series B | 0 |
| 4/2023 | Mercy BioAnalytics | Series A | 0 |
| 7/2022 | Animol Discovery | Series B | 0 |
| 7/2022 | Enko Chem | Series C | 0 |
| 10/2022 | LevitasBio | Series C | 35M |
| 9/2021 | AgBiome | Series D | 0 |
| 3/2020 | Biotalys | Series C | 11.2M |
| 7/2022 | Animol Discovery | Series B | 0 |
| 7/2022 | Enko Chem | Series C | 0 |
| 6/2022 | Vizgen | Series C | 0 |
| 3/2022 | Sherlock Biosciences | Series B | 0 |
| 1/2022 | Ori Biotech | Series B | 0 |
| 12/2021 | SkylineDx | Venture Round | - |
| 9/2021 | AgBiome | Series D | 0 |
| 4/2021 | Vizgen | Series B | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 6/2020 | Enko Chem | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
